BioMarin's hemophilia A gene therapy hits goal in phase 3, teeing up FDA filing despite durability doubts

Sixteen months after a stinging FDA rejection, BioMarin Pharmaceutical looks to have the data it needs to win approval for its hemophilia A gene therapy in the U.S. The study found bleeding episodes remained very rare two years after the administration of valoctocogene roxaparvovec (ValRox).